Pathalys Pharma, a biopharmaceutical company based in Research Triangle Park, NC, has raised $105 million in Series B funding to support its late-stage development of treatments for kidney disease.
Investment to Drive Clinical Trials and FDA Submission
The funding round was led by TCGX and included investments from JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, along with continued support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group.
The capital will be used to finalize the ongoing clinical trials for upacicalcet, a novel calcimimetic, and to prepare for the New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA). Additionally, the funds will help accelerate preapproval commercialization efforts.
Focus on Advanced Kidney Disease Therapies
Pathalys Pharma is focused on developing advanced therapeutics for the management of End-Stage Kidney Disease (ESKD). Its lead asset, upacicalcet, aims to improve the treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients. The company is also exploring other potential treatments to address unmet needs in ESKD care.
This latest round of funding will support Pathalys’ mission to bring innovative solutions to the kidney disease community and improve patient outcomes.
